Pirfenidone for Progressive Fibrotic Sarcoidosis

Inclusion Criteria: * Diagnosis of sarcoidosis * Pulmonary function testing with a Composite Physiologic Index (CPI) score of greater than 40 * Patient must have evidence of \>20% fibrosis on high resolution cat scan * Patients must be on a stable prednisone therapy for sarcoidosis for at least two months and no change in other immunosuppressives in the two months prior to entry into study * Age greater than 18 and less than 90. * Able to provide written informed consent for participation in the study Exclusion Criteria: * Patients receiving therapy for precapillary pulmonary hypertension. * Patients with liver disease Childs class 3 or 4 * Patients with a left ventricular ejection fraction of less than 40% * Patients receiving more than 20 mg prednisone daily or its equivalent * Patients with massive hemoptysis within prior three months. Patients with mycetomas are eligible as long as no massive hemoptysis in prior three months. * Patients with clinically important co-existing disease which in the opinion of the investigator is likely to affect patient's chance for survival during the course of the study * Patient who is pregnant, lactating, intending to become pregnant during the study, or child bearing capacity who is not willing to use appropriate birth control methods approved by investigator